R-Gene 10
(Arginine)Phase 2Small molecule
R-Gene 10 is one of 105 small molecule programs targeting Thalassemia. It is currently in Phase 2.
5
Indications
12
Total Trials
2
Active Trials
104
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
98 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
PIASKY
RochePhase 3
Tepadina
Jazz PharmaceuticalsPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sickle Cell Disease2 trials
Argininosuccinic Aciduria1 trial
6 more indications
Encephalopathy1 trial
MRI1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
R-GENE 10
NDA NDA016931
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Arginine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPharmacia and Upjohn